DM if you're interested. Also selling Kolliphor el liquid to be used for the vehicle formulation as used in the KY19382 trial. Can ship worldwide.
*FYI, KY19382 is a growth agonist working on the activator of Wnt/Ξ²-catenin signaling
KY19382 study: https://pubmed.ncbi.nlm.nih.gov/33751552/
More digestible info video: https://youtu.be/P9pYHfYaqME?t=28
- >!Funny Valentine (Part 7)!<
- >!Tooru (Part 8)!<
- >!Kira Yoshikage (Part 4)!<
- >!Diavolo/Doppio (Part 5)!<
- >!Enrico Pucci (Part 6)!<
- >!Composite Dio Brando/DIO!<
- >!Kars (Part 2)!<
Above is my ranking of JoJo antagonists, with a weird mix of objective and subjective factors like how well the character relates with their theme, novelty they bring, their purpose, how much I like them etc.
I am ready to receive your opinions, rankings, and complaints/downvotes in comment section.
I think Iβve taken too much dexamphetamine and I feel terribly uncomfortable with a rapid heartbeat. I currently have on hand Pindol which is a beta blocker - mostly beta type 1 - would using be beneficial or counter intuitive leading to paradoxical alpha adrenergic vasoconstriction? Any advice is appreciated as Iβm not feeling well at all.
Thanks
what would he think of the imperials,stormcloaks and thalmor?
In molecular design, structural, pharmacological and chemical information can be interconnected by computational estimations of binding free energies. Using a combined FEP approach to examine both mutagenesis and ligand SAR, we designed new analogues of the A2AAR antagonist series of chromones. Subsequent crystal structures supported the rational design of these compounds, linking the structural and energetic understanding on ligand binding.
Abstract
We present a robust protocol based on iterations of free energy perturbation (FEP) calculations, chemical synthesis, biophysical mapping and Xβray crystallography to reveal the binding mode of an antagonist series to the A2A adenosine receptor (AR). Eight A2AAR binding site mutations from biophysical mapping experiments were initially analyzed with sidechain FEP simulations, performed on alternate binding modes. The results distinctively supported one binding mode, which was subsequently used to design new chromone derivatives. Their affinities for the A2AAR were experimentally determined and investigated through a cycle of ligandβFEP calculations, validating the binding orientation of the different chemical substituents proposed. Subsequent Xβray crystallography of the A2AAR with a low and a high affinity chromone derivative confirmed the predicted binding orientation. The new molecules and structures here reported were driven by free energy calculations, and provide new insights on antagonist binding to the A2AAR, an emerging target in immunoβoncology.
https://ift.tt/37CGvG9
